Drugs / Frevecitinib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05006521 | Jul 2021 → Dec 2023 | — | Kinaset Therapeutics Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07532265 | Jun 2026 → Nov 2027 expected | asthma | Kinaset Therapeutics Inc | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-01-29 | Kinaset Therapeutics Inc | Regulatory Kinaset Therapeutics Announces FDA Clearance of IND Application for frevecitinib (KN-002) in Asthma Treatment kinasettherapeutics.com ↗ |
| 2024-05-21 | Kinaset Therapeutics Inc | Results Kinaset Therapeutics Debuts Positive Outcomes Data from Phase 1b Study of KN-002 at the 2024 American Thoracic Society (ATS) International Conference kinasettherapeutics.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Frevecitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07532265 ↗ |
| Known as | KN-002 | “Frevecitinib (KN-002) delivered via a dry powder inhaler (DPI)” NCT07532265 ↗ |
| Modality | Small molecule | — CHEMBL6068013 ↗ |
| Route | Inhaled | “KN-002 dry powder inhaler” NCT05006521 ↗ |